Patient and public involvement in numerical aspects of trials (PoINT) : exploring patient and public partners experiences and identifying stakeholder priorities by Goulao, Beatriz et al.
RESEARCH Open Access
Patient and public involvement in
numerical aspects of trials (PoINT):
exploring patient and public partners
experiences and identifying stakeholder
priorities
Beatriz Goulao* , Hanne Bruhn, Marion Campbell, Craig Ramsay and Katie Gillies
Abstract
Background and aims: Patient and public involvement is increasingly common in trials, but its quality remains
variable in a lot of settings. Many key decisions in trials involve numbers, but patients are rarely involved in those
discussions. We aimed to understand patient and public partners’ experiences and opinions regarding their
involvement in numerical aspects of research and discuss and identify priorities, according to multiple stakeholders,
around the most important numerical aspects in trials to involve patients and the public in.
Methods: The study had two stages: (1) online focus groups with patient and public partners recruited via online
platforms and analysed using inductive thematic analysis and (2) online priority setting meeting with UK- and
Ireland-based stakeholders and following James Lind Alliance methodology. Pre-selected numerical aspects were
introduced prior to the meeting and discussed and prioritised based on a voting system.
Results: In stage 1, we held two focus groups with patient and public partners (n = 9). We identified four themes
in the analysis: “Determinants of PPI in numerical aspects”, “Identity and roles”, “Impact of involving patients and the
public in numerical aspects”. Patient and public partners believed being involved in numerical aspects of research is
important and should be facilitated, but communication about these aspects needs to be clearer. An environment
and relationship with researchers that facilitates that will include time for discussion, support to improve knowledge
and confidence, clear language and definitions and trust. Patient and public partners perceive their role as bringing
an outsider perspective and were mainly interested in involvement in assumptions and dissemination of
quantitative research. They believed this can lead to more transparency and improve their experience by making
involvement more meaningful.
In stage 2, we identified twelve numerical aspects of trials to be prioritised. We held a priority setting meeting with 14
stakeholders, which led to the selection of three priority numerical aspects in patient and public involvement: target
differences, interpretation of results and cost-effectiveness. Participants felt all aspects should be considered for
involvement and their communication needs to ensure a shared level of understanding to avoid power imbalances.
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Conclusions: Our work shows the importance of involving patient and public partners in numerical aspects of trials by
assessing their experiences and motivations for the first time and discussing and prioritising which numerical aspects
of trials are the most important for patients and the public to contribute to. Our research provides a platform for future
efforts to improve patient and public involvement in trials and a prioritised set of future research foci.
Background
Involvement of patients and/or public in research
(herein referred to as Patient and Public Involvement
(PPI)) is about carrying out research with or by members
of the public, including patients (http://www.invo.org.
uk/). PPI activity has become increasingly common for
three main reasons: it makes research better, for ex-
ample by improving recruitment to trials [1]; its sup-
porters believe it is the right thing to do, particularly
when research is publicly funded; it is a requirement
from major funders, including the National Institute for
Health Research (NIHR) in the UK [2].
In a trial context, patient and public partners have to
date been primarily involved in steering committees,
ethical review, and protocol development [3], but in-
volvement remains variable in many settings [4, 5]. One
particular area which has received little attention in trials
is involvement in its numerical aspects, even though
there is increased interest in involving patients in meth-
odological aspects of trial design [6]. Trials are heavily
quantitatively focussed and key decisions are based on
numerical aspects (for example, what the target differ-
ence or the randomisation ratio should be etc.). Improv-
ing involvement and communication related to these
aspects could help develop strong and productive
relationships, the number one methodological priority
for patient and public involvement in clinical trials [7].
Statisticians and health economists have raised the im-
portance of patient and public involvement in the design
and analysis of quantitative research with perceived
benefits including more robust data interpretation and
research [8, 9]. We recently conducted a survey of UK-
based trialists and found the extent to which patients
and the public are involved in numerical discussions var-
ies considerably and that trialists find the communica-
tion of numerical and statistical aspects challenging, but
important. Key barriers to improve patient and public
involvement in numerical aspects of research included a
perceived lack of interest from patient and public part-
ners as well as a lack of understanding about how and
when this type of involvement should happen [10].
To our knowledge, there has been no previous re-
search to understand patient’s and the public’s perspec-
tives and interest in involvement in numerical aspects of
trials. If there is interest, then what numerical aspects
should we be looking at? Our work sought to address
that gap and was divided into two stages: stage 1,
understand patient and public partners’ experiences and
opinions regarding their involvement in numerical as-
pects of research and trials, and, stage 2, discuss and
identify priorities, according to multiple stakeholders,
around the most important numerical aspects in trials to
involve patients and the public in.
Methods
Stage 1: Focus groups with patient and public partners
To gain an understanding of patient and public opinions
and perspectives of involvement with numerical aspects
of research and trials, two focus groups were conducted.
Eligible participants were adults, UK-based patient and
public partners (defined as patients and members of the
public with previous experience of being involved in
research). Participants were recruited via two main
channels: open adverts (via email, Twitter and People in
Research) and targeted invitation through existing PPI
groups. We aimed to recruit a maximum of five partici-
pants per focus group following recent guidelines on
conducting online group discussions [11].
Focus groups were facilitated by a member of the re-
search team (BG) who was assisted by a colleague (HB
or Rumana Newlands) at each focus group. The semi-
structured topic guide covered the following: experiences
of PPI (for example, what stages of research they had
been involved in), experiences of involvement in numer-
ical aspects of research, barriers and facilitators to in-
volvement in numerical aspects of research and
consequences of involvement in numerical aspects of re-
search. The discussion was kept open in terms of type of
research (any type of quantitative research was relevant,
not just trials). However, to exemplify opportunities for
involvement in numerical aspects, we used trials as a
case study. Specifically, we used a diagram discussing
different stages in trials (from trial design to its dissem-
ination) and an example of a numerical aspect, non-
inferiority margins, to aid discussion.
Participants taking part in the focus group were
invited to submit basic demographic data (gender, age
category, ethnicity, and previous involvement experi-
ence). The focus groups were held remotely on Zoom
and audio-recorded and lasted 2 h. The audio-recordings
were transcribed verbatim, checked for accuracy and
identifiable information redacted.
The data were analysed using an iterative thematic ap-
proach [12]. The first full transcript was coded inductively
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by one researcher (BG) and a preliminary thematic
framework was developed. A second researcher (HB)
applied the framework to the first full transcript. A dis-
cussion about disagreements and fit of the thematic
framework and its appropriateness was held until
agreement was reached and the agreed framework was
reapplied. Word and Excel were used to conduct the
thematic analysis.
Stage 2: Prioritisation exercise
2A) Numerical aspects to prioritise
To identify the numerical aspects of trials to include in
the priority setting meeting, we conducted a systematic
review of methods to elicit patient and public’s opinions
on numerical aspects of research. The review’s details
will be published separately, but the review’s protocol is
available upon request. In summary, potentially relevant
titles and abstracts were screened by one reviewer (BG),
with any uncertainties discussed with a second reviewer
(MC, KG, or CR). Six randomly selected abstracts
(around 1% of the total number of abstracts retrieved)
were reviewed independently by a second reviewer (MC,
KG, or CR) for quality assurance. Full-text articles were
obtained for the titles and abstracts identified as poten-
tially relevant. These were provisionally categorised ac-
cording to method of elicitation of patient/public views
(if detailed in the abstract). A reviewer (BG) screened
the full-text articles and extracted information, after hav-
ing screened and extracted information from a practice
sample of articles. Where there was uncertainty regard-
ing whether or not a study should be included for data
extraction, the opinion of a second reviewer (MC, KG,
CR) was sought, and the study discussed until consensus
was reached. Data were extracted verbatim on the meth-
odological details by one author (BG), including type of
article, year of publication, field, aim, participants in-
volved, method used for elicitation of numerical aspects,
numerical aspects being elicited and reasons to involve
non-experts.
The review was additionally supplemented with infor-
mation collected in a previous survey of UK trialists con-
ducted by our group [10]. Specifically, the question from
the survey about current practice in terms of involving
patients and the public in numerical aspects of trials was
used to supplement the literature review list. The survey
included 187 respondents and collected data from June
to July 2019.
Finally, the full list of all identified numerical aspects
extracted was collated and discussed as a group, which
included the study core team and collaborators: a statis-
tician (BG), trial methodologist (KG), chief investigators
(CR, MC), a patient partner (Richard Caie) and a health
economist (Dwayne Boyers). At this point, three new
aspects were added to the list.
2B) Priority setting meeting
The priority setting meeting was a half day event, held
remotely, of plenary and small group discussion, chaired
by a James Lind Alliance (JLA) Senior Adviser. We
brought together representatives from key stakeholder
groups to determine the top 3 list of priorities from the
numerical aspects identified in the previous stage. We
followed JLA guidelines to conduct online group discus-
sions and aimed to have a maximum of 15 participants
since it would allow us to hold three smaller group dis-
cussion with 5 participants each [11].
The priority setting methodology was an adaptation of
the standard approach described in the JLA Guidebook,
namely using small and whole group discussions in a
meeting with a particular emphasis on the top 3 [13].
Adaptions were related to the online nature of the meet-
ing, as well as the fact that we had fewer aspects to pri-
oritise than a traditional JLA priority setting exercise.
The session was half day event instead of a full day to
avoid screen fatigue; for that reason and given the num-
ber of aspects discussed, we compacted breakout ses-
sions as described in the next paragraph.
All attendees were provided with the list of numer-
ical aspects in advance of the meeting, as well as lay
explanations of what each aspect meant, to allow time
to familiarise themselves with the aspects and con-
sider their thoughts on the importance of each one.
A presentation about the meeting’s aims and other
relevant documents, including participants’ introduc-
tions, were sent ahead of the meeting. A JLA facilita-
tor along with two facilitators (BG, HB) led each of
three small groups, which consisted of even represen-
tation of the stakeholder groups. The facilitators acted
as neutral guides for the process and ensured equal
participation to minimise authority effects. After an
introductory plenary session with the entire group,
the three small groups were convened and asked to
discuss and prioritise three top aspects. These initial
small groups were then mixed for the second round
of discussion and a second prioritisation to ensure ex-
posure to a range of ideas and eliminate the potential
bias of group think. The exception was patient part-
ners, who were allocated the same moderator (who
did not participate in the discussion) in both rounds
of discussion. Finally, the small groups all came back
together in a plenary session to vote on the final
prioritised list. Participants were invited to select two
aspects that they felt should be prioritised in terms of
patient and public involvement in numerical aspects
of trials by voting anonymously via SurveyMonkey
[14]. The three items with the highest percentage of
votes were selected as the top 3. Participants were
asked to reflect on the selection. Stata 16 [15] was
used to summarise the priority setting results.
Goulao et al. Trials          (2021) 22:499 Page 3 of 12
Results
Stage 1: Focus group with patient and public partners
We conducted two focus groups in December 2020 with
a total of nine participants. One of the nine participants
did not submit their basic demographic data. Most of
the participants were older than 55 and the majority
were white. All participants had previous experience of
being involved in research as a patient or public partner,
but the range of experiences varied from more experi-
enced patient and public partners that had been involved
in the design of projects and in applying for funding to
patient and public partners that had just started their
involvement journey and had limited knowledge of the
research lifecycle. More details are available in Table 1.
We identified three main themes in our analysis: (1)
determinants of patient and public involvement in nu-
merical aspects of research, (2) identity and role and (3)
impact of involving patients and the public in numerical
aspects. Each theme was then divided into sub-themes
and they are described below. The themes identified in
our analysis are presented in Fig. 1. Table 2 summarises
sub-themes and includes illustrating quotes. Each quote
identifies the participant (P) and the focus group (FG)
using their ID and FG number.
Theme 1: Determinants of patient and public involvement
in numerical aspects of research
Theme 1 focused on factors identified by participants as
influencing involvement in numerical aspects. These de-
terminants were split into four sub-themes: relationship
with researcher, self-confidence, communication of
numerical aspects and their perception of the general
public’s understanding and relationship with numbers
and statistics.
Participants identified the research team’s environ-
ment and their relationship with researchers as key in
making them feel comfortable with being involved in
numerical aspects. Feeling safe and like you can speak
up, having enough time to discuss topics, feeling the re-
searchers have a flexible approach and listen to patient
and public partners were all considered important
facilitators.
“I think that is where a good researcher is worth
their weight in gold you know, if you can engage
with someone from the off and empathise with
where they’re sitting at that moment in time and be
interested, you can get a lot out of them.” [P2, FG1]
Numerical aspects were seen as particularly challen-
ging to discuss and even intimidating for some partici-
pants, so the feeling of confidence in asking questions
was highlighted as a determinant in whether patients
and the public get involved. This was influenced by
whether the environment felt safe and there was trust in
the relationship with the researcher.
“So I think it’s having the right environment, it’s like
you say, it’s getting the right people involved but
not… it depends what you mean by the right people
of course, but also having people that are maybe
confident but not over confident and willing to ask
the stupid question.” [P3, FG1]
Participants strongly emphasised the importance of
communicating about numerical aspects in a clear and
non-technical way to get patient and public partners in-
volved. Lack of definitions of technical language avail-
able outside of meetings was a barrier in involving
patients and the public with participants recommending
alternative resources and modes of delivery of informa-
tion to overcome this barrier.
“Somehow or another, I think there needs to be a
statistics for dummies book. We had, several years
ago now […] a speaker at one of the NCRI
consumer forum meetings […] he came and talked
to us, and somehow or another, statistics became
very human, and it needs someone like him,
someone with his skills, to write statistics for
dummies.” [P1, FG2]
Determinants of patient and public involvement in nu-
merical aspects mentioned above were seen as a reflection
of a wider cultural and societal context, including the
general public’s perceptions of statistics and numbers.
Table 1 Focus group participant characteristics (stage 1)
Characteristics Frequency













Previous experience of being a patient
and public partner in research
Yes 9
No 0
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This was both a potential challenge to get people inter-
ested in numerical aspects, but also a reason to involve pa-
tient and public partners in discussions to help make the
connection between numbers and people.
“Could I raise my usual point here that about 20%
of the Scottish and probably the UK population
really struggle with numbers and being on the very
verge of innumeracy, so that’s an awful lot of
people, so I suppose any message must get across to
the general public using diagrams or hail and
damnation on the other side because “Our side is
right and these numbers prove that they’re right”.”
[P4, FG1]
Theme 2: Identity and role
Participants described what they think their role should
be in numerical aspects. They also pointed out that pa-
tient or public partners’ characteristics may play a role
in their interest and motivation in getting involved and
that might bias the responses obtained.
Participants saw negotiating expectations about their
potential role in numerical aspects of research as an es-
sential first step so they have the opportunity to be more
involved, if they wish to.
“when I get invited to join a panel, I ask for
expectations, we set expectations to where do we sit
in the greater scheme of things; how does this
impact or influence x, and y, z. Are we just here to
be a tick box exercise, or are we here to help,
especially if they are tied to strategic blah, blah,
blah?” [P4, FG2]
Participants felt strongly about the importance of in-
volving patients and the public in the assumptions that
go into defining numerical aspects and the analysis in re-
search (i.e. at the start of process), but they were not as
convinced about their involvement in the actual analysis.
They were also interested on the translation and dissem-
ination of the outputs to a wider audience.
“I think we need the opportunity to be asking
questions during the analysis stage. So that we’re
seeing interim data, we’re seeing the ideas evolving
as the analysis proceeds, we need to be able to look
at that and ask questions. We don’t need to be
involved in how you calculate number here or an
equation there.” [P1, FG2]
“So I think we should leave the statisticians to do
the real heavy duty stuff, but I think we need to be
involved at both the start and the end of the process
so that the ordinary person in the street can
understand and see what’s going on.” [P4, FG1]
Patient and public involvement can bring sense-
checking and an outside perspective to numerical
aspects.
“So in effect you need us because we’re actually
pointing out to you, you’re trying to do what [name
Fig. 1 Visual representation of the thematic analysis results (stage 1)
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Table 2 Focus group analysis themes (Stage 1)









Quality of interaction with research, including
empathy and trust that facilitates and motivates
patient and public partners
“It’s doing it in such a way that you’re not
devaluing the other person; you’re not making
them feel as though they are stupid, and you
really want to engage with them and understand





Being able to question researchers and their
assumptions
“But I’d like to learn a bit more, so I could ask
questions and start to be more effective in this
kind of setting where there’s a whole bunch of
things I don’t know about, as well as the
numerical stuff. But I sense that the clinicians
aren’t that confident either and they just get in a




The use of jargon and the inaccessibility of
definitions and resources to help patient and public
partners participate in number related discussions
“... You need wordsmiths. And there are very
good technical writers who can write plain
language, ... … You want the kind of science
journalist that you see writing on the BBC
website. Or contributing to radio and television
programmes. You want someone that’s got a bit
of scientific knowledge, you want someone






Observations about general public’s perceptions of
statistics and numbers as a potential determinant of
interest and understanding of research’s numerical
aspects
“… That’s quite scary when education’s so poor.
Well it’s not the education that’s so poor, it’s the
emphasis I think perhaps on numbers, there’s an
awful lot of people very scared of numbers.” [P2,
FG1]
Identity and role Patient and public
partner’s role
What patient and public partners believe their role
should be in relation to numerical aspects; their
interest in helping define the context and
assumptions behind deriving a number, as well as
its interpretation
“Yeah, it’s our job to decide what numbers
you’re going to look for and then decide
whether you’ve found the right numbers from





How motivation and personal experience can lead
to more interest in being involved in numerical
aspects of research; reflection on what that means
for involvement in these aspects
“For me the problem lies in when you ask these
people to put a number, what influences them
to reach the number five? There are the
variables again you know, you’ve got your
people who are poor, your people who are rich,
your people who have false teeth and just put,
“I’m not bothered”” [P5, FG1]
Impact Transparency Ability to scrutinise researcher’s decisions on
numerical aspects leads to more transparency in
the whole process
“I think transparency would be a main thing, like
how can researchers, how can organisations,
how can care providers be more transparent and
disclose information which allows the patient,
the public, to be able to make informed
decisions.” [P4, FG2]
Feeling useful Belief that numerical aspects are crucial in the
research and policy making process and, therefore,
being involved in them leads to a better
understanding of the pathway and higher quality
involvement
“I think if I’m getting to improve or getting
better at writing lay summaries, then I actually
have to be able to understand the numerical
aspects of the initial document that I have to
read through, and then produce something
which is then understandable without taking
away from the meaning of the stats. [It is] about
around understanding that journey, that
pathway, and if you just provide the data
without facilitating the understanding, then you
just have numbers, you’re just dishing out
numbers to someone and then they don’t
understand.” [P4, FG2]
Improved research As outsiders bringing questions in, patient and
public partners can help improve the quality of the
research done and disseminated
“It’s the forcing them to think outside of their
micro analytical numbers based box and forcing
them to actually step into somebody else’s shoes
and look at the work is actually intensely
important however it’s done.” [P1, FG1]
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redacted] says you shouldn’t do, you’re trying to
answer two questions at the same time [by asking
about non-inferiority margins directly] and you’re
bringing in variables and muddying the water so to
speak.“ [P5, FG1]
When presented with the diagram showing the stages
of the research lifecycle as well as the non-inferiority
margin example, there was general agreement that pa-
tient and public partners should have the opportunity to
discuss and contribute to the definition of target differ-
ences. However, there were disagreements about how
(involvement in defining a number or in its assump-
tions?). Participants did not suggest any other numerical
aspects to be involved in, except one (clinical equipoise).
This seemed, at least partially, because patient and pub-
lic partners felt uninformed about the wider research
process and design of clinical trials.
Participants saw patient and public partner’s charac-
teristics (their previous experience with numbers, their
skills and their motivations) as key in whether they
would have an interest in involvement in numerical as-
pects of trials and in how the communication of numer-
ical aspects should be done.
“In one sense you might almost say you need a set
of professional PPI people who kind of are self-
aware enough to know that they shouldn’t push
their agenda, have been to enough meetings so that
they know when to shut up and when to just put
their opinion across. But you’re always going to
have problems with recruiting people off the street
so to speak because you just don’t know what
they’re bringing with them.” [P5, FG1]
Theme 3: Impact of involving patients and the public in
numerical aspects
Theme 3 focuses on the potential impact that involving
patients and the public can have. Participants felt being
able to scrutinise researcher’s assumptions, including in
the numerical aspects of research, and to discuss them
openly would lead to more transparency in research; this
was considered an extremely important and positive
consequence of patient and public involvement and it
can lead to better research.
“[…] so then it comes back to transparency, is there
willingness from researchers, or from clinicians, or
from the gatekeepers, whoever holds this
information, for it to be accessible to patients. And
I think if patients are involved in the start, then they
can start to sort of highlight these issues or how is
this going to be accessible to people afterwards.”
[P4, FG2]
Another potential positive impact of involving patients
and the public in numerical aspects is their feeling of ac-
complishment and of being able to provide more mean-
ingful comments to lay summaries or discussions of
results.
“Well, I think you get the opportunity to make a
more meaningful contribution into the discussion
[if patients and the public are involved in numerical
aspects]. You know, there’s a lot of malarky about
what impacts do involve patients have. Well, I have
long believed that that’s the wrong way of looking
at it, because what we do is we create a culture
change and you don’t measure a culture change
through simple impact in numbers” [P1, FG2]
In general, offering the opportunity of involving pa-
tients and the public in numerical aspects of research
was seen as positive, but a potential issue was how time
consuming this could be for both researchers and pa-
tient and public partners.
Stage 2: Priority setting
The twelve numerical aspects identified in advance of the
priority setting meeting are presented in Table 3. Clinical
equipoise, suggested in the patient and public partner’s
focus groups, had already been identified in our review.
The priority setting meeting consisted of 14 stakeholders,
comprising 3 patient partners, 1 chief investigator (clin-
ical), 1 commissioner, 1 health economist, 1 trial method-
ologist (statistics), 1 trial coordinator, 1 trial manager, 1
patient and public involvement coordinator, 1 statistician,
2 experts in patient and public involvement in numerical
aspects, 1 statistician/health economist.
Figure 2 shows the final ordering of the numerical
aspects prioritised. The top three aspects selected were
Table 2 Focus group analysis themes (Stage 1) (Continued)
Theme Sub-theme Meaning Illustrating citation
Time consuming Involvement is time consuming and this leads to
exclusion of certain groups of people which is
problematic; involvement in numerical aspects of
research may be challenging due to taking time
both for researchers and patient and public
partners
“I think for the researcher, it might be if you
have got too many people questioning your
research, and then that might make the process
a bit longer, and then you’ve got all these
deadlines that are coming up with the ethics
panel, and all of these findings of patients.“ [P4,
FG2]
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target differences, interpretation of results and cost-
effectiveness. Expected contamination, clinical equipoise,
randomisation allocation, stop/go criteria and data mon-
itoring committees were not part of any stakeholders’
top 2.
During the discussions that supported the voting
process, participants felt that involvement in numerical
aspects of trials was extremely important and that priori-
tisation could help achieve it, but all numerical aspects
should be considered for future involvement and re-
search. There was discussion on the weight of responsi-
bility of selecting three priority aspects on behalf of a
wider group of stakeholders and that led to nervousness
in some participants. Participants felt that any discussion
about numerical aspects needs to start with common
ground definitions about what these aspects are to en-
sure a meaningful discussion and avoid power imbal-
ances. Feelings of anxiety when discussing numerical
aspects were expressed due to their technical nature.
After the voting in the final plenary session, there was a
discussion about the top 3. All participants felt that the
final top 3 reflected their small group discussions
throughout the morning. Target differences were con-
sistently selected as part of participant’s top 3 because
they were seen as the closest numerical aspects to
patient’s experience (“what is meaningful to patients?”);
interpretation of results and dissemination of findings
were considered important to improve communication
with patients and trial participants and to ensure imple-
mentation of findings; value for money was also seen as
close to patient’s experience and as a key piece in health
policy decision making.
Discussion
We have conducted the first study exploring patient and
public partners’ experiences and motivations regarding
their involvement in numerical aspects of research and
trials, as well as the first priority setting exercise identify-
ing what numerical aspects of trials are the most import-
ant for patients and the public to contribute to. We
found that patients and the public believe their involve-
ment in numerical aspects is important, particularly in
its assumptions and communication, and could lead to
improved transparency and more meaningful involve-
ment. Stakeholders selected target differences, interpret-
ation of results and cost-effectiveness as their top 3
numerical aspects of trials to involve patients and the
public in.
Communication of and jargon related to numerical as-
pects was identified as a key barrier to patient and public
Table 3 Numerical aspects selected to be discussed at the priority setting meeting (stage 2)
Aspects Meaning
Target differences (clinically meaningful
difference, non-inferiority margins)
This is the difference that will make researchers and clinicians conclude a treatment is better or
good enough compared with a control
Risk/benefit trade-off In a clinical trial, we usually test to find out whether a treatment gives more benefit than another.
However, there could be risks or burdens to the patient there are different depending on the
treatment.
Expected contamination People in the control group unintentionally take the treatment or people in the treatment group
unintentionally do not.
Clinical equipoise A state of uncertainty in terms of what treatment option is best.
Randomisation allocation ratio Ratio in which patients are allocated to receive a treatment compared with a control. It is usually
done on a 1:1 basis which means the same number of people will get randomised to the
treatment and the control.
Discussions about representativeness of sample Discussion about the characteristics of people included in research studies and whether they are
representative of the population of interest
Recruitment and retention projections Recruitment is the process through which an individual is recruited as a study participant.
Participant retention is the engagement of the participant in the research study.
Stop/go criteria Often trials include specific criteria to decide on whether they should move forward, i.e. collect all
data as planned or stop due to unfeasibility of recruitment, treatment delivery or due to treatment
harm.
Data monitoring committee data discussions A committee that may be established by the trial sponsor to assess at intervals, the progress of a
clinical trial, the safety data, and the critical efficacy endpoints, and to recommend to the sponsor
whether to continue, modify, or stop a trial. (INVOLVE; webpage consulted in 09/11/2020)
Missing data When a participant outcome is unavailable, due to a missing questionnaire or non-attendance to
a trial related clinical appointment
Cost-effectiveness (value for money) Economic analysis that views effects in terms of overall health specific to the problem, and
describes the costs for some additional health gain (e.g. cost per additional stroke prevented).
Interpretation of trial results and their
dissemination
Discussion about trial results (presented as numbers, for example, treatment effects) and how to
present them to patients and the public
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involvement. This is not new—Gamble et al. raised this
issue almost ten years ago [16], but it has clearly
remained a challenge [17]. Other determinants of patient
and public involvement in numerical aspects of research
raised were the environment and relationship with re-
searchers which has been found to be a main influencer
on patient and public involvement quality [18]. This can
affect self-confidence which can, in turn, affect patient
and public partners’ perceived ability to question re-
searchers. This is in line with focus group findings dis-
cussing patient and public involvement in trials [17], and
the determinants found here are also the foundation to
building strong and productive working relationships be-
tween researchers and patient or public partners, the
number one methodological priority for PPI in trials [7].
General perceptions about numbers and statistics, as
well as numeracy levels, may influence whether people
decide to get involved in numerical aspects of research;
they may also be the reason why patient and public in-
volvement is important to these aspects—a way of trans-
lating numbers into stories. Any strategy to achieve this
needs to account for the low levels of numerical and
statistical literacy in the general population [8] and adapt
communication to reach a diverse group of people.
Patients and the public perceived their role in
numerical aspects as sense-checkers bringing an outside
perspective supporting past self-descriptions of PPI con-
tributors as “challenging outsiders” [19]. It was suggested
their involvement should happen in a funnel format:
helping researchers develop the assumptions that go into
defining numbers and statistical models and aiding
interpretation and dissemination of results. Their inter-
est in the “statistical nitty-gritty” was less obvious, as
they felt like they did not have the expertise to be in-
volved. This proposed model of involvement goes in line
with Hannigan’s reflections of PPI in statistics [8]: in-
volving patients and the public in the actual analysis
process might be an inefficient use of PPI resources
since it demands considerable technical knowledge;
however, quantitative data are numbers with a context
and patient and public partners could help statisticians
identify and understand that context. We found patient
and public partner’s role expectations should be set up
from the start which agrees with other research about
patient and public involvement in general [5]. A lot of
the patient partners felt like they did not have enough
information about stages of research or numerical as-
pects of trials and recommended resources such as in-
duction books and presentations as potential solutions.
Who can and would like to be involved in numerical
aspects of trials was raised in the focus groups, with the
perception that personal experience may affect motiv-
ation and that patients might be biased when giving
their opinions on numerical aspects. This issue is raised
in research related to PPI in health economics modelling
with suggestions that patients involved need to be able
to keep a neutral view [9]. In previous work, we found
around half of UK trialists responding a survey about
PPI believed patient and public partners had to have
specific skills to be involved in numerical aspects; these
included numeracy, statistical knowledge and under-
standing of trials. However, other fields outside of health
Fig. 2 Number of responses that classified each numerical aspect as their top 2; each participant could vote twice so the total is 28 (14
participants × 2) (stage 2)
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research have used participatory methods to involve
non-experts in model development [20] and other statis-
tical aspects [21].
Target differences (clinically meaningful differences
and non-inferiority margins) were selected by 13 out of
the 14 stakeholders as one of their top 2 numerical
aspects to involve patients and the public. Methods to
include patient’s views on clinically meaningful differ-
ences indirectly exist, via for example anchor-based
approaches. However, the relevance of their methods
and results is not currently discussed with patients [22].
When it comes to direct elicitation or opinion seeking
methods for clinically meaningful differences, patients
have been involved but their focus tends to be on clini-
cians [23]. Researchers have not, to our knowledge, in-
volved patients and the public in defining non-inferiority
margins despite recent calls to do so [24] and controver-
sies over how current margins are defined [25].
Interpretation and discussion of results was selected
by 6 out of 14 stakeholders as one of their top 2 numer-
ical aspects. The importance of appropriate dissemin-
ation of trial results and patient and public involvement
in its development has only recently been on the re-
search agenda [26] and, even though there is some evi-
dence on how to communicate numerical evidence to
the public [27], its role in trials needs to be further ex-
plored. Cost-effectiveness was selected by 3 out of 14
stakeholders as their top 2 numerical aspect. Methods to
involve patient and public in cost-effectiveness and
health economics in trials have been recently discussed
[28] with experts believing patients are a key stakeholder
in this process [9].
Strengths and limitations
Our study was initially planned to be delivered face-to-
face (focus groups and priority setting meeting) and had
to be adapted to an online setting given the COVID-19
pandemic. Online settings might have advantages (such
as wider geographical reach), but they also have disad-
vantages (exclusion of potential participants that do not
have access to the technology needed; lack of non-verbal
cues may lead to more difficult communication). How-
ever, the facilitators pro-actively attempted to ensure
that the views of all the participants were heard—check-
ing back with each individual to ensure all their points
had been covered. We also advertised the focus groups
widely and ensured it was clear we would provide sup-
port for participants to take part if needed. We worked
to adapt our methods and followed James Lind Alliance
guidance on the best practice to conduct online priority
setting meetings. Focus group participants and stake-
holders that accepted to take part in our priority setting
meeting are, however, likely to have a particular interest
in the topic and might not represent the views of other
patient and public partners or experts in trials. More-
over, patient and public partners may have higher educa-
tion and possibly numeracy levels than the general
population [19]. Numerical aspects of trials are challen-
ging to discuss due to their technical nature and, for that
reason, we provided a thorough guide of what we meant
by each aspect, as well as a video presentation of what
the priority setting meeting would entail—this is a
strength of the study. We also explicitly addressed ner-
vousness and the potential for power imbalances from
the start of the meeting, reassuring everyone about their
important voice in the conversation, and splitting up the
groups to allow each patient/public partner to stay with
the same facilitator throughout. Going forward, we
would recommend a pre-meeting to discuss any queries
related to the technical aspects as well as the opportun-
ity for patient partners to meet up in a separate online
room to discuss their views. Patient and public partners,
as well as the other stakeholders, felt like their views
were considered and reflected on the top three
priorities.
Conclusion
Many trial key decisions are based on numbers. Keeping
numbers out of the discussion with patients, and/or
making the discussion difficult by not communicating
about them appropriately, can perpetuate power imbal-
ances between patient and public partners and re-
searchers [19]. In order to ensure PPI in trials is not
tokenistic, patients should be given the opportunity to
contribute to its numerical aspects. We have shown that
for patient and public views to be appropriately heard,
the environment in which these discussions are held is
important (allowing ample time for discussion; where re-
searchers listen; and where any perceived lack of confi-
dence with numbers is supported); jargon needs to be
omitted and lay definitions provided, and the relation-
ship and trust established between the research team
and the patients and public is paramount. Our research
provides a platform for future efforts to improve patient
and public involvement in trials and a prioritised set of
future research foci.
Future research recommendations
Future research should focus on improving involvement
of patients and the public in numerical aspects of trials.
This will unavoidably involve developing methods to im-
prove communication about statistics and numerical as-
pects, including training materials that allow more
meaningful conversations between patient partners and
researchers. The training materials could be aimed at
both patient partners (to improve their understanding of
the impact of statistics in trials and clinical practice) and
trialists (to improve communication about numerical
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aspects). Materials aiming to explain numerical aspects
should be developed to reach people independent of
their numerary levels. There is scope to explore the
adaptation of methods such as Bayesian elicitation [29],
typically used with clinicians, to incorporate patient’s
views in numerical aspects of trials. These types of
methods could be used to discuss all numerical aspects
presented in our work, but their acceptability and feasi-
bility need to be assessed before implementation in
trials.
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